Menter, A., Blauvelt, A., Strober, B., Colombo, M., Kisa, R., Kundu, S., Banerjee, S., & Leonardi, C. (2020). Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis. SKIN The Journal of Cutaneous Medicine, 4(6), s72. https://doi.org/10.25251/skin.4.supp.72